Conference Coverage

Clinical advances drive lung cancer staging, classification changes


 

AT THE IASLC WORLD CONFERENCE

References

The proposed revision would continue to group in the M1a category cases with pleural/pericardial effusions, contralateral/bilateral lung nodules, contralateral/bilateral pleural nodules, or a combination of multiple parameters. However, single metastatic lesions in a single distant organ would be reclassified as M1b, and multiple lesions in a single organ or multiple lesions in multiple organs would be reclassified as M1c.

Pages

Recommended Reading

ASCO: Precision medicine initiatives take wing
MDedge Internal Medicine
Cigarettes account for slightly under half of smoking-related cancer deaths
MDedge Internal Medicine
Invasive approaches ‘overused’ for evaluating pulmonary nodules
MDedge Internal Medicine
AATS: Metformin linked to better progression-free survival in early-stage NSCLC
MDedge Internal Medicine
Lung cancer biomarker moves into the clinic
MDedge Internal Medicine
Vemurafenib looks promising for several nonmelanoma malignancies
MDedge Internal Medicine
IASLC issues new tobacco declaration
MDedge Internal Medicine
Share of lung cancer patients who never smoked is rising
MDedge Internal Medicine
New cancer cases to reach nearly 2.4 million in 2035 – AACR
MDedge Internal Medicine
Workshop tackles finer points of lung cancer screening
MDedge Internal Medicine